Advertisement

Beta-Rezeptoren-Blocker

Definition, Einteilung, Chemie Pharmakologie Neurobiochemie, Wirkmechanismus
  • U. Borchard
  • M. Gastpar
  • J. Rimpel
Chapter

Zusammenfassung

β-Rezeptorenblocker haben heute ihren festen Platz in der Behandlung der koronaren Herzerkrankung, der Hypertonie und von Herzrhythmusstörungen. Weiterhin sind sie erfolgreich bei folgenden Erkrankungen eingesetzt worden: hypertrophische obstruktive Kardiomyopathie, hyperkinetisches Herzsyndrom, hypotone tachykarde Kreislaufregulationsstörungen, Hyperthyreose, Tremor, Migräne, Angstsyndrom, psychischer Streß, Glaukom, Phäochromozytom und portale Hypertension (Frishman 1980, Borchard 1988).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Borchard U (1988) Klinische Pharmakologie der Betarezeptorenblocker. Aesopus, BaselGoogle Scholar
  2. Borchard U, Hirth C, Hafner D (1984) Pharmakologische Eigenschaften von (—)— und (+)—Penbutolol. In: Gerlach E, Kubler W (Hrsg) Betablocker-Expertengespräch, Standortbestimmung Penbutolol. Informed, Gräfelfing, S 19–23Google Scholar
  3. Borchard U, Hafner D, Hirth C (1985) In vitro studies on the pharmacological properties of diacetolol, the major metabolite of acebutolol in man. Arch Int Pharmacodyn Ther 274: 4–17Google Scholar
  4. Cruickshank JM (1980) The clinical importance of cardioselectivity and lipophilicity in betablokkers. Am Heart J 100: 160–178PubMedCrossRefGoogle Scholar
  5. Daul A, Schemmuth R, Brinkmann M, Bock KD, Borchard U, Brodde OE (1985) The significance of intrinsic sympathomimetic activity (ISA) of 3-blockers for its effect on human lymphocyte f32- adrenoceptor (R) density. J Hypertens 3: 400 401Google Scholar
  6. Frishman WH (1980) Clinical pharmacology of the beta-adrenoceptor blocking drugs. Appleton-Century-Crofts, New YorkGoogle Scholar
  7. Göthert M, Hentrich F, Greschuchna D, Rohm N (1984) Präsynaptische Betaadrenozeptoren mit steigernder Wirkung auf die Noradrenalinfreisetzung in der Vena saphena und Arteria pulmonalis des Menschen. Therapiewoche 34: 63–87Google Scholar
  8. Hafner D, Berger F, Borchard U, Kullmann A, Scherlitz A (1988) Electrophysiological characterization of the class III activity of sotalol and its enantiomers: new interpretation of use dependent effects. Drug Res 8: 231–236Google Scholar
  9. Hoffer BJ, Siggins GR, Oliver AP, Bloom FE (1971) Cyclic AMP mediation of norepinephrine inhibition in rat cerebellar cortex: a unique class of synaptic responses. Ann NY Acad Sci 185: 531–549PubMedCrossRefGoogle Scholar
  10. Hoffer BJ, Siggins GR, Oliver AP, Bloom FE (1973) Acitivation of the pathway from locus coeruleus to rat cerebellar Purkinje neurons: pharmacological evidence of noradrenergic central inhibition. J Pharmacol Exp Ther 84: 553–569Google Scholar
  11. Johnson ES, Roberts MHT, Sobieszek A, Straughan DW (1969) Noradrenaline sensitive cells in cat cerebral cortex. Int J Neuropharmacol 8: 549–556PubMedCrossRefGoogle Scholar
  12. Johnson RH (1982) Beta-blockers in management of migraine. In: Zanchetti A (ed) Advances in (3-blocker therapy II. Excerpta Medica, Amsterdam Oxford Princeton, pp 194–210Google Scholar
  13. Johnsson G, Regardh CG (1976) Clinical pharmacokinetics of (3-adreno-receptor blocking drugs. Clin Pharmacokinet 1: 233–263PubMedCrossRefGoogle Scholar
  14. Knauf H, Schäfer-Korting M, Mutschler E (1981) Pharmakokinetik und biologische Wirkdauer von (3-Rezeptorenblockern bei Niereninsuffizienz. Internist 22: 616–621PubMedGoogle Scholar
  15. Koebe P, Reinke A, Rost R, Nicolai R, Schwan U (1984) Der dosisabhängige Einfluß kardioselektiver und nicht kardioselektiver 3-Rezeptorenblocker auf Stoffwechsel-und Kreislaufparameter während körperlicher Belastung. In: Jeschke D (Hrsg) Stellenwert der Sportmedizin in Medizin und Sportwissenschaft. Springer, Berlin Heidelberg New York Tokyo, S 530–536CrossRefGoogle Scholar
  16. Koella WP (1976) Die zentralen Wirkungen der Betablocker — anatomische, physiologische und pharmakologische Befunde. In: KIELHOLZ P (Hrsg) Betablocker und Zentralnervensystem. Hans Huber, Bern Stuttgart Wien, S 20–34Google Scholar
  17. Koella WP, Smythies JR, Levy CK, Czigman JS (1960) Modulatory influence on cerebral cortical optic response from the carotid sinus area. Am J Physiol 199: 381–386PubMedGoogle Scholar
  18. Lohmöller G, Conca W, Pötzel C (1987) Klinische Bedeutung der ISA des Betablockers Carteolol. Med Klin 82: 647–650Google Scholar
  19. Lundborg P, Aström H, Bengtsson C, Fellenius E, VON Schenck H, Svensson L, Smith U (1981) Ef- fect of (3-adrenoceptor blockade on exercise performance and metabolism. Clin Sci 61: 299–305PubMedGoogle Scholar
  20. Margules DL (1971) Alpha and beta adrenergic receptors in amygdala: reciprocal inhibitors and facilitators of punished operant behavior. Eur J Pharmacol 16: 21–26PubMedCrossRefGoogle Scholar
  21. Pfaffenrath V (1987) Die Bedeutung der Beta-1Selektivität bei der Migräne. In: LOHMANN FW (Hrsg) Die Bedeutung der Beta-1-Selektivität in Klinik und Praxis. De Gruyter, Berlin New York, S 9–29Google Scholar
  22. Schulz V (1984) Hemmung der Thrombozyten-aggregation durch 3-Blocker. Fortschr Med 47: 1203–1205Google Scholar
  23. Shimizu N, Imamoto K (1970) Fine structure of the locus coeruleus in the rat. Arch Histol Jap 31: 229–238PubMedCrossRefGoogle Scholar
  24. Taylor SH, Silke B, Lee PS (1982) Intravenous betablockade in coronary heart disease. Is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful? N Engl J Med 306: 631–635PubMedCrossRefGoogle Scholar
  25. Tyrer PJ (1980) Use of [3-blocking drugs in psych- iatry and neurology. Drugs 20: 300–308PubMedCrossRefGoogle Scholar
  26. Ungerstedt U (1971) Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand [Suppi] 367: 1–48Google Scholar
  27. Vogt M (1954) The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs. J Physiol 123: 451–481PubMedGoogle Scholar
  28. Wellstein A, Palm D, Belz GG, Leopold G, Buh-Ring KU, Pabst J (1986) Konzentrationskinetik von Propranolol, Bisoprolol und Atenolol beim Menschen mit chemischer Detektion und einem subtypselektiven (3-Adrenozeptor-Assay. J Cardiovasc Pharmacol 8 [Suppl 11]: 48–53Google Scholar
  29. Adler L, Angrist B, Peselow E, Corwin J, Maslansky R, Rotrosen J (1986) A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 149: 42–45PubMedCrossRefGoogle Scholar
  30. Ananth J, Lin K-M (1986) Propranolol in psychiatry: therapeutic uses and side effects. Neuro-psychobiology 15: 20–27Google Scholar
  31. Atsmon A (1976) Early observations on the effect of propranolol on psychotic patients. Adv Clin Pharmacol 12: 86Google Scholar
  32. Atsmon A, Blum I (1970) Treatment of acute porphyria variegata with propranolol. Lancet i: 196–197Google Scholar
  33. Bacher NM, Lewis MA (1980) Low dose propranolol in tardive dyskinesia. Am J Psychiatry 137: 495–497PubMedGoogle Scholar
  34. Ballenger JC (1986) Pharmacotherapy of the panic disorders. J Clin Psychiatry 47 [Suppl 61: 27–32Google Scholar
  35. Benkert O, Hippius H (1986) Psychiatrische Pharmakotherapie, 4. Aufl. Springer, Berlin Heidelberg New York TokyoCrossRefGoogle Scholar
  36. Borgesen SE (1976) Treatment of migraine with propranolol. Postgrad Med J 52 [Suppl 41: 163–165Google Scholar
  37. Brewer C (1972) Beneficial effect of beta-adrenergic blockade on “exam. nerves”. Lancet ii: 435Google Scholar
  38. Burrows GD, Davies B, Fail L, Poynton C, Steven-Son H (1976) A placebo controlled trial of diazepam and oxprenolol for anxiety. Psychopharmacology 50: 177–179PubMedCrossRefGoogle Scholar
  39. Cleeves L, Findley LJ (1988) Propranolol and propranolol-LA in essential tremor: a double blind comparative study. J Neurol Neurosurg Psychiatry 51: 379–384PubMedCrossRefGoogle Scholar
  40. Covelli V, Antonaci F, Pagliarulo E (1983) Propra-nolol: further evidence of its antianxiety effects. Acta Ther 9: 367–373Google Scholar
  41. DE Oliveira LLL, DE Miranda P, Campos S DES (1983) Propranolol in the treatment of anxiety: a double-blind study. Folha Med 86: 83–86Google Scholar
  42. Diener HC, Scholz E, Dichgans J, Gerber WD, Jack A, Bille A, Niederberger U (1989) Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials. Ann Neurol 25: 125–130PubMedCrossRefGoogle Scholar
  43. Drew PJT, Barnes JN, Evans SJW (1985) The effect of acute ß-adrenoceptor blockade on examination performance. Br J Clin Pharmacol 19: 783–786PubMedCrossRefGoogle Scholar
  44. Duhigg WJ (1985) Effects of propranolol on ataxic syndromes. Arch Neurol 42: 15PubMedCrossRefGoogle Scholar
  45. Eccleston D, Fairbairn AF, Hassanyeh F, Mcclelland HA, Stephens DA (1985) The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia. Br J Psychiatry 147: 623–630PubMedCrossRefGoogle Scholar
  46. Eckerskorn U, Hockwin O (1988) Spezielle Erfas-sung von Beta-Blocker-Nebenwirkungen am Auge. In: Grosdanoff P et al. (Hrsg) Beta-Rezeptoren und Beta-Rezeptorenblocker. De Gruyter, Berlin New York, S 481–485Google Scholar
  47. Emrich HM (1985) ZNS-Aktivität von Beta-Rezeptorenblockern und ihre Anwendung bei psychotischen Erregungszuständen. In: Hippius H, Schemer G (Hrsg) Beta-Rezeptorenblocker in der Neurologie und Psychiatrie–Interdisziplinäre Bewertung. Zuckschwerdt, München Bern Wien, S 65–75Google Scholar
  48. Folgering H, Rutten H, Roumen Y (1983) Beta-blockade in the hyperventilation syndrome: a retrospective assessment of symptoms and complaints. Respiration 44: 19–25PubMedCrossRefGoogle Scholar
  49. Gallant DM, Swanson WC, Guerrero-Figueroa R (1973) A controlled evaluation of propranolol in chronic alcoholic patients presenting the symptomatology of anxiety and tension. J Clin Pharmacol 13: 41–43Google Scholar
  50. Gastpar M, Hobi V, Pöldinger W, Goldsmith S, Maly V, Sci-Imidlin PE (1980) A placebo-controlled comparative study of the combined effects of oxprenolol and clomipramine in depressed patients. Int Pharmacopsychiatry 15: 24–58PubMedGoogle Scholar
  51. Granville-Grossman KL, Turner P (1966) The effect of propranolol on anxiety. Lancet 1: 788–790PubMedCrossRefGoogle Scholar
  52. Greenblatt DJ, Koch-Weser J (1973) Adverse re actions to propranolol in hospitalized medi- cal patients: a report from the Boston collabo- rative drug surveillance program. Am Heart J 86: 478–484PubMedCrossRefGoogle Scholar
  53. Greendyke RM, Kanter DR, Schuster DB, Verstrea-Te S, Wooton J (1986) Propranolol treatment of assaultive patients with organic brain disease: a double-blind crossover, placebo-controlled study. J Nerv Ment Dis 174: 290–294PubMedCrossRefGoogle Scholar
  54. Gundert-Remy U (1988) Wechselwirkungen von Beta-Blockern mit anderen Medikamenten. In: GROSDANOFF P et al. (Hrsg) Beta-Rezeptoren und Beta-Rezeptorenblocker. De Gruyter, Berlin New York, S 129–134Google Scholar
  55. Hafner J, Milton F (1977) The influence of propranolol on the exposure in vivo of agoraphobics. Psychol Med 7: 417–425CrossRefGoogle Scholar
  56. Hallstrom C, Treasaden I, Edwards JG, Lader M (1981) Diazepam, propranolol and their combination in the management of chronic anxiety. Br J Psychiatry 139: 417–421PubMedCrossRefGoogle Scholar
  57. Imhof PR, Blatter K, Fuccella LM, Turri M (1969) Beta-blockade and emotional tachycardia; radiotelemetric investigations in ski jumpers. J Appl Physiol 27: 366–369PubMedGoogle Scholar
  58. Janka UH (1988) Therapeutische Probleme der Beta-Blocker-Therapie bei Diabetes mellitus. In: GROSDANOFF P et al. (Hrsg) Beta-Rezeptoren und Beta-Rezeptorenblocker. De Gruyter, Berlin New York, S 369–373Google Scholar
  59. Johnson G, Singh B, Leeman M (1976) Controlled evaluation of the beta-adrenergic blocking drug oxprenolol in anxiety. Med J Aust 1: 909PubMedGoogle Scholar
  60. Joseph R, Steiner TJ, Schultz LUC, Clifford Rose F (1988) Platelet activity and selective ß-blockade in migraine prophylaxis. Stroke 19: 704–708PubMedCrossRefGoogle Scholar
  61. Kales A, Cadieux R, Soldatos CR, Tan TL (1979) Successful treatment of narcolepsy with propranolol: a case report. Arch Neurol 36: 650–651PubMedCrossRefGoogle Scholar
  62. Kathol RG, Noyes R JR, Slymen DJ, Crowe. RR, Clance J, Kerber RE (1980) Propranolol in chronic anxiety disorders. Arch Gen Psychiatry 37: 1361–1365PubMedCrossRefGoogle Scholar
  63. Kilminster SG, Lewis MJ, Jones DM (1988) Anxio-lytic effects of acebutolol and atenolol in healthy volunteers with induced anxiety. Psychopharmacology 95: 245–249PubMedCrossRefGoogle Scholar
  64. Koller WC (1986) Dose-response relationship of propranolol in the treatment of essential tremor. Arch Neurol 43: 42–43PubMedCrossRefGoogle Scholar
  65. Koller WC, Vetere-Overfield B (1989) Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 39: 1587–1588PubMedCrossRefGoogle Scholar
  66. Kramer B, Kubler W (1984) Absetzphänomene nach chronischer ß-Blockade. Dtsch Med Wochenschr 109: 465–471PubMedCrossRefGoogle Scholar
  67. Lader M (1988) ß-Adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry 49: 213–223PubMedGoogle Scholar
  68. Ladewig D, Levin P, Gastpar M, Gerking P, Rom E (1977) The use of beta-blockers in the management of withdrawal syndromes. In: ADAMS C et al. (eds) Beta-blockers in the central nervous system. Huber, Bern, pp 149–157Google Scholar
  69. Larsen TA, Teravainen H (1981) Beta-blockers in essential tremor. Lancet 11: 533CrossRefGoogle Scholar
  70. Larsen TA, Calne DB (1983) Essential tremor. Clin Neuropharmacol 6: 185–206PubMedCrossRefGoogle Scholar
  71. Liebowitz MR, Gorman JM, Fyer AJ (1985) Social phobia. Review of a neglected anxiety disorder. Arch Gen Psychiatry 42: 729–736Google Scholar
  72. Lipinski JF, Zubenko GS, Barreira P, Cohen BM (1983) Propranolol in the treatment of neuroleptic-induced akathisia. Lancet ii: 685–686Google Scholar
  73. Lydtin H, Lohmöller G (1977) Beta-RezeptorenBlocker. Aesopus, LuganoGoogle Scholar
  74. Manchanda R, Hirsch SR (1986) Does propranolol have an antipsychotic effect? A placebo-controlled study in acute schizophrenia. BrJ Psychiatry 148: 701–707CrossRefGoogle Scholar
  75. Mattes JA (1986) Psychopharmacology of temper outbursts. J Nerv Ment Dis 174: 464–470PubMedCrossRefGoogle Scholar
  76. Matthys H (1988) Der Einfluß von Beta-Blockern auf die Atemwege. In: Grosdanoff P et al. (Hrsg) Beta-Rezeptoren und Beta-Rezeptorenblocker. De Gruyter, Berlin New York, S 389–399Google Scholar
  77. Medical Research Council Working Party On Mild To Moderate Hypertension (1981) Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 11: 539–543Google Scholar
  78. Medical Research Council Working Party On Mild To Moderate Hypertension (1985) MRC trial of treat-ment of mild hypertension: principal results. Br Med J 291: 97–103CrossRefGoogle Scholar
  79. Meibach RC, Dunner D, Wilson LG, Ishiki D, Dager SR (1987) Comparative efficacy of propranolol, ch1ordiazepoxide, and placebo in the treatment of anxiety: a double blind trial. J Clin Psychiatry 48: 355–358PubMedGoogle Scholar
  80. Munjack DJ, Rebal R, Shaner R, Staples F, Braun R, Leonard M (1985) Imipramine versus propranolol for the treatment of panic attacks: a pilot study. Compr Psychiatry 26: 80–89PubMedCrossRefGoogle Scholar
  81. Munjack DJ, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, Mcmanus M, Mcdowell D, Palmer R, Leonard M (1989) Alprazolam, propranolol, and placebo in the treatment of panic disor-der and agoraphobia with panic attacks. J Clin Psychopharmacol 9: 22–27PubMedGoogle Scholar
  82. Neftel KA, Adler RH, Kappeli L, Rossi M, Dolder M, Kaser HE, Bruggesser HH, Vorkauf H (1982) Stage fright in musicians: a model illustrating the effect of beta blockers. Psychosom Med 44: 461–469PubMedGoogle Scholar
  83. Novac A (1986) Improvement in tardive dyskinesia and MMPI scores with propranolol. J Clin Psychiatry 47: 218–219PubMedGoogle Scholar
  84. Noyes R, Anderson D, Clancy J, Crowe R, Slymen D, Ghoneim M, Hinrichs J (1984) Diazepam and propranolol in panic disorders and agoraphobia. Arch Gen Psychiatry 41: 287–292PubMedCrossRefGoogle Scholar
  85. Ochs HR, Greenblatt DJ, Ochs-Verburg B (1984) Propranolol interactions with diazepam, lorazepam, and alprazolam. Clin Pharmacol Ther 36: 451–455PubMedCrossRefGoogle Scholar
  86. Peet M, Bethell MS, Coates A, Khamnee AK, Hall P, Cooper SJ, King DJ, Yates RA (1981) Proprano-lol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo. BrJ Psychiatry 139: 105–111Google Scholar
  87. Ramsay I, Greer S, Bagley C (1973) Propranolol in neurotic and thyrotoxic anxiety. BrJ Psychiatry 122: 555–560CrossRefGoogle Scholar
  88. Rausch JL, Janowsky DS, Golshan S, Kuhn K, Risch SC (1988) Atenolol treatment of late luteal phase dysphoric disorder. J Affective Disord 15: 141–147CrossRefGoogle Scholar
  89. Saul P, Jones BP, Edwards KG, Tweed JA (1985) Randomized comparison of aenolol and place- bo in the treatment of anxiety: a double-blind study. EurJ Clin Pharmacol 28 [Suppl]: 109–110CrossRefGoogle Scholar
  90. Schou M, Vestergaard P (1987) Use of proprano lol during lithium treatment: an enquiry and a suggestion. Pharmacopsychiatry 20: 131PubMedCrossRefGoogle Scholar
  91. Shehi M, Patterson W (1984) Treatment of panic attacks with alprazolam and propranolol. Am J Psychiatry 141: 900–901PubMedGoogle Scholar
  92. Smith RC, Wilkinson J, Hull RL (1985) Glucagon for propranolol overdose. JAMA 254: 2412PubMedCrossRefGoogle Scholar
  93. SOYKA D (1987) Kopfschmerz und Migraine. In: Flügel KA (Hrsg) Neurologische und Psychiatrische Therapie. Perimed, Erlangen, S 509–516Google Scholar
  94. Tanna VT, Pennigroth RP, Woolson RF (1977) Pro-pranolol in the treatment of anxiety neurosis. Compr Psychiatry 18: 319–326PubMedCrossRefGoogle Scholar
  95. Tyrer PJ, Lader MH (1973) Effects of betaadrenergic blockade with sotalol in chronic anxiety. Clin Pharmacol Ther 14: 418–426PubMedGoogle Scholar
  96. Tyrer PJ, Lader MH (1974) Response to propranolol and diazepam in somatic and psychic anxiety. Br Med J 1: 14–16CrossRefGoogle Scholar
  97. Wheatley D (1969) Comparative effects of propranolol and chlordiazepoxide in anxiety states. BrJ Psychiatry 115: 1411–1412CrossRefGoogle Scholar
  98. Wikstrand J, Westergren G, Berglund G, Bracchetti D, VAN Couter A, Feldstein CA, Ming KS, Kuramoto K, Landahl S, Meaney E et al. (1986) Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study. JAMA 255: 1304–1310Google Scholar
  99. Zubenko GS, Lipinski JF, Cohen BM, Barreira PJ (1984) Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatry Res 11: 143–149PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1992

Authors and Affiliations

  • U. Borchard
  • M. Gastpar
  • J. Rimpel

There are no affiliations available

Personalised recommendations